Buried inside a Nature Reviews Drug Discovery commentary published this month is an argument that should be circulating in every BD&L war room and regulatory affairs suite right now: the bottleneck in medicines development has shifted from science to data infrastructure. Not data volume — data quality, interoperability, and the institutional capacity to convert real-world signals into regulatory currency.
The street has been pricing RWE as a nice-to-have. The signal here is that it is becoming a hard prerequisite — and the sponsors who have built the machinery to generate it are about to hold a structural timing advantage over everyone else.
The Old Playbook Is Running Out of Road
The dominant assumption for the past decade has been that a well-run Phase 3 RCT, cleanly executed, remains the gold standard submission pathway — and that RWE is a supplementary instrument, useful for label expansions and post-market commitments, but peripheral to the core approval strategy. That framing is increasingly wrong, and the regulatory architecture is quietly being rewritten around it.
The FDA’s August 2023 guidance on the use of real-world data and real-world evidence to support regulatory decision-making made explicit what had been implicit for years: observational data drawn from electronic health records and medical claims can carry evidentiary weight in initial approval dossiers — provided the data meet standards for fitness-of-purpose, transparency, and pre-registration. The EMA, for its part, ran an adaptive pathways pilot from March 2014 through July 2016, receiving 62 applications and selecting 18 for face-to-face meetings, and has since embedded iterative evidence generation into its regulatory philosophy. Two of the world’s largest drug agencies are pointing in the same direction.
The counterintuitive read here is this: the companies most exposed to this shift are not the small biotechs — it is the large-cap sponsors with entrenched submission teams optimized for a single workflow. Mid-sized organizations with nimble regulatory functions and modern data infrastructure are positioned to move faster into adaptive and RWE-supported pathways than legacy organizations whose internal systems were built around the 1990s RCT paradigm.
Who Captures the Timing Advantage
Consider what “data readiness” actually means in practice. The FDA’s Center for Biologics Evaluation and Research formalized its requirement for CDISC’s SENDIG-AR v1.0 standard for nonclinical data submissions on March 26, 2024. That is not a technical footnote — it is a signal that standardization requirements are expanding, not contracting. Sponsors whose data systems cannot natively generate CDISC-compliant outputs face retrofit costs and review-cycle delays that compound across a portfolio.
The winners in this environment are sponsors who have made what amounts to an infrastructure bet ahead of the regulatory mandate. That includes organizations that have integrated EHR and claims data pipelines early — not for post-market surveillance as an afterthought, but as a prospective evidence-generation strategy baked into trial design. The FDA’s separate guidance on assessing EHRs and medical claims data for regulatory decision-making creates a direct pathway for this, but only for sponsors whose data infrastructure can demonstrate fitness-of-purpose criteria at the time of submission.
The losers are sponsors treating RWE as a project to be stood up when the FDA asks for it. By that point, the data provenance questions — Was the collection pre-specified? Were endpoints defined before data lock? Can you demonstrate the population matches the labeled indication? — are unanswerable retrospectively. A Complete Response Letter citing data quality deficiencies, governed under 21 CFR 314.110, is not a recoverable position in a competitive indication where a rival has already cleared the bar.
Bavencio’s Breakthrough Therapy Designation in November 2015 for Merkel cell carcinoma and its subsequent accelerated approval demonstrated that non-traditional evidence packages can move through the agency when the scientific argument is tight and the data foundation is credible. The lesson absorbed by most sponsors was “pursue BTD.” The sharper lesson was “build the data system that makes the evidence package credible in the first place.”
The Directive for Decision-Makers
If you are running a Phase 2 asset in any indication where real-world patient populations diverge meaningfully from RCT-eligible populations — oncology, cardiometabolic, CNS, rare disease — your regulatory strategy document should already contain a prospective RWE module. If it does not, your PTRS estimate is optimistic, and your timeline to NDA/BLA is understated by at least one review cycle.
The more immediate pressure point is M&A diligence. Any acquirer evaluating a mid-stage pipeline asset in 2026 should be running a parallel data infrastructure audit alongside the clinical package review. The question is no longer only “does the Phase 2 signal support advancement?” — it is “can this sponsor generate the evidentiary package that the FDA’s current framework demands?” A brilliant mechanism of action sitting on a fragmented, non-standardized data architecture is a liability disguised as a pipeline. Risk-adjusted NPV calculations that ignore data readiness are systematically mispricing deals.
The next signal to watch: FDA’s expanding guidance on data standards adoption timelines and whether PDUFA VIII negotiations in the coming cycle introduce formal RWE readiness benchmarks as part of the pre-submission meeting framework. If they do, the sponsors who built the infrastructure early will not just have a compliance advantage — they will have a first-mover window in indications where their competitors are still retrofitting databases while the review clock runs.
References
- Nature Reviews Drug Discovery — “Better data for better medicines: a path to data-driven medicines regulation”
- FDA — “Considerations for the Use of Real-World Data and Real-World Evidence To Support Regulatory Decision-Making for Drug and Biological Products” (August 2023)
- FDA — “Real-World Data: Assessing Electronic Health Records and Medical Claims Data To Support Regulatory Decision-Making for Drug and Biological Products”
- EMA — “Final Report: Adaptive Pathways Pilot” (2016)
- CDISC — “Supporting Submission and Standardisation of Data: An EMA Update” (2024)
- UroToday — “Bavencio Receives FDA Breakthrough Therapy Designation” (2015)
- FDA — Data Standards Adoption Guidance Document
Moe Alsumidaie is Chief Editor of The Clinical Trial Vanguard. Moe holds decades of experience in the clinical trials industry. Moe also serves as Head of Research at CliniBiz and Chief Data Scientist at Annex Clinical Corporation.
